Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial

Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results from its FASTR randomized pilot study, evaluating the Reprieve System for patients with ADHF compared to optimal diuretic therapy (ODT).